Status:
COMPLETED
Study of the Role of PCSK9 and FXR in the Physiopathology of the Joint Dyslipidemia Associated to the Human Immunoresistance
Lead Sponsor:
Nantes University Hospital
Conditions:
Obesity
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Experimental results are strongly suggesting that PCSK9 and FXR could occur in the physiopathology of human joined dyslipidemia. But no data in the literature can validate the potential role of these ...
Eligibility Criteria
Inclusion
- corporal mass index \> 40 kg/m² or \> 35 kg/m² associated to a co-morbidity resistant to a diet
- bariatric surgery planned
- no lipid-lowering drugs during 4 weeks before surgery
- no treatment by metformin during 4 weeks before surgery
- no treatment by glitazones during 8 weeks before surgery
- age of the patient between 18 and 65 years
- consent form signed
- patient with social insurance
Exclusion
- age inferior to 18 years
- women pregnant
- coagulation troubles
- surgery contraindicated
- Chronic hepatitis B or C active
- VIH infected
- other chronic hepatic disease
- patient with dyslipidemia under lipid-lowering drugs in secondary prevention of a cardiovascular pathology
- Type 2 diabetes under insulinosensitivator treatments
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2013
Estimated Enrollment :
111 Patients enrolled
Trial Details
Trial ID
NCT00422006
Start Date
February 1 2008
End Date
November 1 2013
Last Update
April 3 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Nantes
Nantes, France, 44093